Thursday, July 3, 2025

Creating liberating content

Synopsys logo is seen displayed on a smartphone with the

A turf war is breaking out in the vast world

Inflammation is the body’s natural response to infection and usually

MUMBAI: Indian entrepreneur and founder of Hong Kong-based The Caravel

Related News

Synopsys logo is seen displayed on a smartphone with the flag of China in the background. Sopa Images | Lightrocket | Getty Images The U.S. government has rescinded its export

A turf war is breaking out in the vast world of digital payments – and the incumbents are suddenly on defense. Tech firms and crypto startups are moving in on

Inflammation is the body’s natural response to infection and usually subsides on its own, when the infection is healed. However, chronic infections in the root canal area cause ongoing inflammation

MUMBAI: Indian entrepreneur and founder of Hong Kong-based The Caravel Group, Harindarpal Singh Banga, and his family are selling around a 2.1% stake in Nykaa worth about $140.3 million (Rs

MUMBAI: RBI has mooted a unique, secure borrower identifier to avoid duplication and misreporting of data with credit bureaus, and to improve loan access for borrowers.“Credit information companies rely on

BENGALURU: Midcap IT firms are poised to outperform large caps in the June quarter, analysts said. Deal signings continued steadily, with minimal large client cutbacks despite ongoing macroeconomic uncertainty, geopolitical

Trending News

A turf war is breaking out in the vast world of digital payments – and the incumbents are suddenly on defense. Tech firms and crypto startups are moving in on

MUMBAI: Indian entrepreneur and founder of Hong Kong-based The Caravel Group, Harindarpal Singh Banga, and his family are selling around a 2.1% stake in Nykaa worth about $140.3 million (Rs

MUMBAI: RBI has mooted a unique, secure borrower identifier to avoid duplication and misreporting of data with credit bureaus, and to improve loan access for borrowers.“Credit information companies rely on

MUMBAI: Shares of HDB Financial Services rose nearly 14% on the day of listing in the stock exchanges closing at Rs 841 against the issue price of Rs 740. At

NEW DELHI: Convenience rules and consumers are now reaching for ready-to-cook (RTC) meals more than ever before. Interestingly, RTC is the only category in packaged food that has doubled in

CHENNAI: Tyre exports from India hit an all-time high of Rs 25,051 crore in FY25, up 9% compared to Rs 23,073 crore clocked in the previous fiscal, commerce ministry data

Hims & Hers brings former Amazon executive into C-suite

Word Count: 343 | Estimated Reading Time: 2 minutes


Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally.

Courtesy: Hims & Hers

Hims & Hers Health on Monday announced Nader Kabbani, a former Amazon executive who helped establish many of its health-care offerings, will join the telehealth company as its chief operations officer.

Kabbani spent nearly 20 years at Amazon, where he oversaw the launch of Amazon Pharmacy, the company’s acquisition of PillPack and its global Covid-19 Vaccination Task Force. He also helped stand up Amazon Kindle, Amazon Logistics, Amazon Music and Prime Video services.

Hims & Hers offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss. The company, which saw revenue increase by 69% last year, said Kabbani will help the company continue to grow and scale.

“Nader’s experience scaling operations at the highest level makes him uniquely qualified to help us build the future of healthcare,” Hims and Hers CEO Andrew Dudum said in a statement.

In addition to his experience at Amazon, Kabbani also held executive leadership roles at the supply chain logistics company Flexport and the warehouse automation company Symbotic.

Stock Chart IconStock chart icon

hide content

Hims & Hers shares over six months.

Hims & Hers shares had a volatile start to the year, notching several double digit moves over the last few months. Investors have been paying close attention to the company’s weight loss offering, which was thrown into question after the U.S. Food and Drug Administration announced changes to the medication supply environment earlier this year.

Shares of the company closed up 23% on April 29, for instance, after Novo Nordisk said it would offer its weight loss drug Wegovy through telehealth providers like Hims & Hers.

The stock was down more than 1% on Monday but was up more than 70% year to date.

Hims & Hers is slated to report earnings after market close.

WATCH: Hims & Hers shares rise as company adds Eli Lilly’s Zepbound

Hims & Hers shares rise as company adds Eli Lilly's Zepbound



Source link

Most Popular Articles

Sign In

Welcome ! Log into Your Account